IMVT Reports $902M Cash, $147.9M Net Loss, $0.73 EPS for Q4 FY2026
Immunovant, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $32.86
-4.9% in 3d after detection
Post-detection moves
1h
—
1d
-4.0%
3d
-4.9%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS